Lantus (insulin glargine) / Sanofi 
Welcome,         Profile    Billing    Logout  
 89 Diseases   30 Trials   30 Trials   3067 News 


«12...56789101112131415...2829»
  • ||||||||||  IDegLira (insulin degludec/liraglutide) / Novo Nordisk, Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Indirect Treatment Comparison (ITC) of IGlarLixi vs. IDegLira in Adults Inadequately Controlled by GLP-1 Receptor Agonists (GLP-1RAs) () -  May 18, 2020 - Abstract #ADA2020ADA_1773;    
    Hypoglycemia comparisons suffered from varying definitions, sulfonylurea (SU) use and eligibility, and few events in the GLP-1 RA arms (incidence: 32% [confirmed ≤3.1 mmol/L, 28% without SU] with IDegLira and 9% or 28% [symptomatic <3.0 or ≤3.9 mmol/L] with iGlarLixi). This ITC shows similar FRC HbA1c glycemic target achievement but suggests divergent differences in other glycemia results and hypoglycemia, likely due to different study design and titration application.
  • ||||||||||  Lantus (insulin glargine) / Sanofi, Trulicity (dulaglutide) / Eli Lilly
    [VIRTUAL] Dulaglutide Improves Kidney Fibrosis Biomarker Levels in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease () -  May 18, 2020 - Abstract #ADA2020ADA_1764;    
    At week 26 and 52 of treatment, urinary C3M levels were significantly higher and serum PRO-C6 levels were significantly lower in the dulaglutide 1.5 mg group compared with insulin glargine group, respectively (Table).In conclusion, dulaglutide was associated with decreased levels of biomarkers for type VI collagen formation and increased type III collagen degradation, suggesting a potential effect to reduce kidney fibrosis. These anti-fibrotic effects could be a potential mechanism for the beneficial effects observed with dulaglutide treatment on CKD in type 2 diabetes.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Basal Insulins in Advanced Renal Failure: Time for a Paradigm Shift () -  May 18, 2020 - Abstract #ADA2020ADA_1289;    
    This single-centered, retrospective, observational study evaluates efficacy and safety of insulin glargine and insulin degludec in CKD with eGFR 60 and below. IDeg has lower rate of hypoglycemia in advanced renal failure T2DM patients and may be a safer option to use in this scenario.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
    [VIRTUAL] Efficacy and Safety of Fast-Acting Insulin Aspart in Adults with T2D with Different Insulin Requirements () -  May 18, 2020 - Abstract #ADA2020ADA_1281;    
    This post-hoc analysis of the 16-week onset 9 trial aimed to confirm this and explore efficacy and safety of FA vs. IAsp, both with insulin degludec, in bolus-experienced adults with T2D (duration ≥10 yrs) by insulin requirement...There was a trend towards lower rates of severe or blood glucose-confirmed hypoglycemia with higher insulin doses at meal test, with a benefit for FA vs. IAsp in the >20 U subgroup. Treatment difference (FA vs. IAsp) in change from baseline in PPG increments was unaffected by bolus insulin dose; however hypoglycemia risk may be lower with FA vs. IAsp in adults with long-standing T2D and high bolus insulin requirements.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Comparison of Two Approaches to Basal Insulin Management for Adults with Type 1 Diabetes Flying across Multiple Time Zones () -  May 18, 2020 - Abstract #ADA2020ADA_1275;    
    Significantly less time was also spent below 250 mg/dL (p<0.01) during eastward travel and <70 (p<0.01) during westward travel on DEG. Inflight CV on DEG was also less during both eastward (43% vs. 49%, p<0.01) and westward (38% vs. 51%, p<0.0001) travel.In conclusion, for adults with T1D undertaking long-haul travel, DEG use was associated with less disruption to glucose control compared to GLA.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Degludec-to-Glargine Transition: The First Real-World Study () -  May 18, 2020 - Abstract #ADA2020ADA_1269;    
    Two patients of T1D had BG300mg/dL, and 0% developed DKA during the transition.Despite clinicians ordering arbitrary doses and timing of iG100 for this transition, patients with T2D maintained their BG in a safe range, but patients with T1D developed more glycemic variability with hypo- and overt hyperglycemia. Using evidence and knowledge of iDeg’s PK and PD, developing consensus guidelines emphasizing safety of patients with T1D undergoing iDeg to iG100 transition is possible.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes () -  May 18, 2020 - Abstract #ADA2020ADA_1238;    
    18 persons with T1DM (age 40±12 yrs, diabetes duration 26±12 yrs, A1C 7.2±0.5 %, 55±6 mmol/mol) were randomized to Gla-300 or Gla-100 titrated for 3 months, followed by 2 month washout, and alternate treatment for 3 more months. Titrated Gla-300 improves glucose control, reduces variability and hypoglycemia risk vs. Gla-100, as predicted from PK/PD differences of individual doses.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Review, Journal:  Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. (Pubmed Central) -  May 9, 2020   
    These advantages can lead to decreased healthcare resource utilization and cost. With this collective knowledge, healthcare providers and payers can make educated and well-informed decisions when determining which treatment regimen best meets the needs of each individual patient.Funding: Sanofi US, Inc.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Retrospective Review of the Impact of a Basal Insulin Formulary Change on a Medicaid Population () -  May 6, 2020 - Abstract #AMCP2020AMCP_94;    
    Basaglar was approved in December 2015 as the first “follow on” insulin product through an abbreviated approval pathway under the Federal Food, Drug, and Cosmetic Act...Members will be included if they had at least one or more 90-day supply or three or more 30-day supply pharmacy claims of Lantus, Toujeo, or Tresiba in the pre-formulary change period (November 1, 2017 to April 30, 2018)... Work in progress Sponsorship: None
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Trial suspension:  Liraglutide Hospital Discharge Trial (clinicaltrials.gov) -  May 4, 2020   
    P4,  N=330, Suspended, 
    Work in progress Sponsorship: None Recruiting --> Suspended
  • ||||||||||  metformin / Generic mfg., Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Journal:  Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? (Pubmed Central) -  Apr 30, 2020   
    Using flash glucose monitoring, insulin glargine 300 U/mL showed less nocturnal hypoglycemia than insulin degludec 100 U/mL . Examination of insulin degludec 100 U/mL nocturnal hypoglycemia by combined oral medications suggested that metformin combination might be the cause of nocturnal hypoglycemia.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Clinical, Review, Journal, Real-World Evidence:  Glargine-300: An updated literature review on randomized controlled trials and real-world studies. (Pubmed Central) -  Apr 23, 2020   
    Gla-300 is one of the newer second-generation basal insulin analogues to have been approved for both type 1 and 2 diabetes. In this article, we review the currently available clinical and real-world data of Gla-300.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Review, Journal:  Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues. (Pubmed Central) -  Apr 23, 2020   
    Moreover, real-world data have been used to assess the effectiveness of these basal insulins during routine clinical practice. Further research is required to determine if the properties of Gla-300 and IDeg may lead to improvements in healthcare-related costs and the quality of life of patients, which are important factors for informing clinical decisions.
  • ||||||||||  Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Trial completion:  A Study of LY2963016 Compared to Lantus (clinicaltrials.gov) -  Apr 22, 2020   
    P3,  N=536, Completed, 
    The use of a needle-free injector can significantly lower the dosage of insulin required to achieve good glycemic control and reduce topical adverse reactions and the fear of injections as well, which help to improve patient compliance. Active, not recruiting --> Completed
  • ||||||||||  Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
    Trial completion, Combination therapy:  A Study of LY2963016 Compared to Lantus (clinicaltrials.gov) -  Apr 22, 2020   
    P3,  N=272, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi, Trulicity (dulaglutide) / Eli Lilly
    Journal, HEOR:  Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. (Pubmed Central) -  Apr 21, 2020   
    We have chosen gliclazide, as a sulfonylurea and Abasaglar, the less expensive among basal insulin analogues...Study findings can provide stakeholders valuable evidence to support the adoption of this cost-effective second- or third-line therapy compared to gliclazide or basal insulin glargine. Dulaglutide cost-effectiveness has been particularly evident in the comparison with basal insulin glargine, indicating that, in patients who have treatment indication, this therapy may be preferred to basalization avoiding related complications and costs.
  • ||||||||||  Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
    Journal:  Low Blood Glucose Index and Hypoglycaemia Risk: Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Type 2 Diabetes. (Pubmed Central) -  Apr 20, 2020   
    Using the LBGI metric, a lower risk of hypoglycaemia with Gla-300 than Gla-100 was observed in all three trials. The finding that differences in LBGI are greater at night is consistent with previously published differences in the pharmacokinetic profiles of Gla-300 and Gla-100, which provides the physiological foundation for the presented results.
  • ||||||||||  Soliqua 100/33 (lixisenatide + insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
    Clinical, Journal:  Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. (Pubmed Central) -  Apr 16, 2020   
    P3
    This article will review 2 basal insulin/GLP-1 agonist combination products, IDegLira and IGlarLixi, which were approved in November 2016. Uncapping the iGlar dose in LixiLan-O and LixiLan-L would not have led to significant improvements in mean A1C reduction in the iGlar arm, supporting the conclusion that iGlarLixi provides additional, clinically-relevant glycemic control versus iGlar alone.
  • ||||||||||  Clinical, Retrospective data, Journal:  Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. (Pubmed Central) -  Apr 13, 2020   
    P3
    When compared with the IDegAsp twice-daily injections, Gla300/Glu basal-bolus therapy might achieve more effective glycemic control without hypoglycemic risk. Dulaglutide demonstrated significantly greater HbA1c reduction with weight loss and lower risk of hypoglycemia compared with active comparators in Chinese patients with T2DM irrespective of baseline HbA1c, with much greater HbA1c reductions in patients with a higher baseline HbA1c.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
    Journal:  Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia? (Pubmed Central) -  Apr 12, 2020   
    Dulaglutide demonstrated significantly greater HbA1c reduction with weight loss and lower risk of hypoglycemia compared with active comparators in Chinese patients with T2DM irrespective of baseline HbA1c, with much greater HbA1c reductions in patients with a higher baseline HbA1c. No abstract available
  • ||||||||||  Lantus (insulin glargine) / Sanofi
    Journal:  Doomed to a vile lot: new taxa, notes, and an updated generic key for the Old World corsairs (Heteroptera: Reduviidae: Peiratinae). (Pubmed Central) -  Apr 9, 2020   
    All of the above taxonomic acts are supplemented with a key to the species of Calistocoris, a key to the species of Pachysandalus, and a key to the peiratine genera of the Old World. Also reported are thirteen new country records for eleven other species: Brachysandalus bicolor (Villiers, 1948) (Kenya, Tanzania); Ectomocoris bimaculatus Schouteden, 1909 (Ghana); Ectomocoris fenestratus (Klug, 1830) (Ghana); Ectomocoris maculicrus (Fairmaire, 1858) (Uganda, Zimbabwe); Lestomerus affinis (Audinet-Serville, 1831) (Malaysia); Lestomerus basilewskyi Villiers, 1962 (Kenya); Lestomerus bicolor (Villiers, 1948) (Kenya); Lestomerus dubius Villiers, 1948 (Cameroon); Pachysandalus schoutedeni Villiers, 1962 (Sudan); Peirates collarti Schouteden, 1931 (Cameroon); Peirates quadrinotatus (Fabricius, 1798) (Malaysia); and Phalantus africanus Stål, 1874 (Ghana).
  • ||||||||||  metformin / Generic mfg., Lantus (insulin glargine) / Sanofi
    [VIRTUAL] Diabetic striatopathy in a patient with hemichorea: a case report (ePoster) -  Apr 9, 2020 - Abstract #EAN2020EAN_725;    
    His medical history included hypertension, atrial fibrillation, previous stroke with no residual disability and poorly controlled type 2 diabetes mellitus on metformin treatment...The patient was initiated on intensive insulin therapy which included insuline glargine (Lantus) 10 units every evening and 12 units of insuline glusine (Apidra ) 3 times a day with meals... Diabetic striatopathy is rare but treatable disorder and should be considered in patients with poorly controlled diabetes who present with hemichorea.